Literature DB >> 20007202

Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Stephen R Cole1, Sonia Napravnik, Michael J Mugavero, Bryan Lau, Joseph J Eron, Michael S Saag.   

Abstract

Plasma human immunodeficiency virus type 1 (HIV-1) viral load is a valuable tool for HIV research and clinical care but is often used in a noncumulative manner. The authors developed copy-years viremia as a measure of cumulative plasma HIV-1 viral load exposure among 297 HIV seroconverters from the Multicenter AIDS Cohort Study (1984-1996). Men were followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the beginning of the combination antiretroviral therapy era (January 1, 1996); the median duration of follow-up was 4.6 years (interquartile range (IQR), 2.7-6.5). The median viral load and level of copy-years viremia over 2,281 semiannual follow-up assessments were 29,628 copies/mL (IQR, 8,547-80,210) and 63,659 copies x years/mL (IQR, 15,935-180,341). A total of 127 men developed AIDS or died, and 170 survived AIDS-free and were censored on January 1, 1996, or lost to follow-up. Rank correlations between copy-years viremia and other measures of viral load were 0.56-0.87. Each log(10) increase in copy-years viremia was associated with a 1.70-fold increased hazard (95% confidence interval: 0.94, 3.07) of AIDS or death, independently of infection duration, age, race, CD4 cell count, set-point, peak viral load, or most recent viral load. Copy-years viremia, a novel measure of cumulative viral burden, may provide prognostic information beyond traditional single measures of viremia.

Entities:  

Mesh:

Year:  2009        PMID: 20007202      PMCID: PMC2878100          DOI: 10.1093/aje/kwp347

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  37 in total

1.  Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

Authors:  R P Bucy; R D Hockett; C A Derdeyn; M S Saag; K Squires; M Sillers; R T Mitsuyasu; J M Kilby
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

2.  An overview of methods for the analysis of longitudinal data.

Authors:  S L Zeger; K Y Liang
Journal:  Stat Med       Date:  1992 Oct-Nov       Impact factor: 2.373

3.  Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.

Authors:  Lauren E Cain; Stephen R Cole; Joan S Chmiel; Joseph B Margolick; Charles R Rinaldo; Roger Detels
Journal:  Am J Epidemiol       Date:  2005-12-21       Impact factor: 4.897

4.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

Review 5.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

6.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

7.  Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.

Authors:  Judith E Sackoff; David B Hanna; Melissa R Pfeiffer; Lucia V Torian
Journal:  Ann Intern Med       Date:  2006-09-19       Impact factor: 25.391

8.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

9.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.

Authors:  Colette Smit; Ronald Geskus; Sarah Walker; Caroline Sabin; Roel Coutinho; Kholoud Porter; Maria Prins
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

10.  Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

Authors:  R D Hockett; J M Kilby; C A Derdeyn; M S Saag; M Sillers; K Squires; S Chiz; M A Nowak; G M Shaw; R P Bucy
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

View more
  54 in total

1.  Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention.

Authors:  Michael J Mugavero; K Rivet Amico; Andrew O Westfall; Heidi M Crane; Anne Zinski; James H Willig; Julia C Dombrowski; Wynne E Norton; James L Raper; Mari M Kitahata; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

2.  Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.

Authors:  Elizabeth L Yanik; Sonia Napravnik; Stephen R Cole; Chad J Achenbach; Satish Gopal; Dirk P Dittmer; Andrew F Olshan; Mari M Kitahata; Michael J Mugavero; Michael Saag; Richard D Moore; W Christopher Mathews; Peter Hunt; Joseph J Eron
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

3.  Recent Thymus Emigrant CD4+ T Cells Predict HIV Disease Progression in Patients With Perinatally Acquired HIV.

Authors:  Ramia Zakhour; Dat Q Tran; Guenet Degaffe; Cynthia S Bell; Elizabeth Donnachie; Weihe Zhang; Norma Pérez; Laura J Benjamins; Gabriela Del Bianco; Gilhen Rodriguez; James R Murphy; Gloria P Heresi
Journal:  Clin Infect Dis       Date:  2016-02-21       Impact factor: 9.079

4.  Chronic kidney disease associated with perinatal HIV infection in children and adolescents.

Authors:  Murli U Purswani; Miriam C Chernoff; Charles D Mitchell; George R Seage; Gaston Zilleruelo; Carolyn Abitbol; Warren A Andiman; Kathleen A Kaiser; Hans Spiegel; James M Oleske
Journal:  Pediatr Nephrol       Date:  2012-02-26       Impact factor: 3.714

5.  Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection.

Authors:  Zaza M Ndhlovu; Samuel W Kazer; Thandeka Nkosi; Funsho Ogunshola; Daniel M Muema; Gursev Anmole; Shayda A Swann; Amber Moodley; Krista Dong; Tarylee Reddy; Mark A Brockman; Alex K Shalek; Thumbi Ndung'u; Bruce D Walker
Journal:  Sci Transl Med       Date:  2019-05-22       Impact factor: 17.956

6.  Bias in the estimation of cumulative viremia in cohort studies of HIV-infected individuals.

Authors:  Maia Lesosky; Tracy Glass; Brian Rambau; Nei-Yuan Hsiao; Elaine J Abrams; Landon Myer
Journal:  Ann Epidemiol       Date:  2019-08-23       Impact factor: 3.797

7.  Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Authors:  Murli U Purswani; Brad Karalius; Tzy-Jyun Yao; D Scott Schmid; Sandra K Burchett; George K Siberry; Kunjal Patel; Russell B Van Dyke; Ram Yogev; Robert H Lurie; Ram Yogev; Margaret Ann Sanders; Kathleen Malee; Scott Hunter; William Shearer; Mary Paul; Norma Cooper; Lynnette Harris; Murli Purswani; Mahboobullah Baig; Anna Cintron; Ana Puga; Sandra Navarro; Patricia Garvie; James Blood; Sandra Burchett; Nancy Karthas; Betsy Kammerer; Andrew Wiznia; Marlene Burey; Molly Nozyce; Arry Dieudonne; Linda Bettica; Susan Adubato; Janet Chen; Maria Garcia Bulkley; Latreaca Ivey; Mitzie Grant; Katherine Knapp; Kim Allison; Megan Wilkins; Midnela Acevedo-Flores; Heida Rios; Vivian Olivera; Margarita Silio; Medea Jones; Patricia Sirois; Stephen Spector; Kim Norris; Sharon Nichols; Elizabeth McFarland; Alisa Katai; Jennifer Dunn; Suzanne Paul; Gwendolyn Scott; Patricia Bryan; Elizabeth Willen
Journal:  Clin Infect Dis       Date:  2015-09-18       Impact factor: 9.079

8.  Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction.

Authors:  Joseph A Delaney; Robin M Nance; Bridget M Whitney; Heidi M Crane; Jessica Williams-Nguyen; Mathew J Feinstein; Robert C Kaplan; David B Hanna; Matthew J Budoff; Daniel R Drozd; Greer Burkholder; Michael J Mugavero; William C Mathews; Richard D Moore; Joseph J Eron; Peter W Hunt; Elvin Geng; Michael S Saag; Mari M Kitahata; Susan R Heckbert
Journal:  Epidemiology       Date:  2019-01       Impact factor: 4.822

9.  Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.

Authors:  Stephen T Wright; Jennifer Hoy; Brian Mulhall; Catherine C Oʼconnor; Kathy Petoumenos; Timothy Read; Don Smith; Ian Woolley; Mark A Boyd
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

10.  Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.

Authors:  Jessie K Edwards; Stephen R Cole; H Irene Hall; W Christopher Mathews; Richard D Moore; Michael J Mugavero; Joseph J Eron
Journal:  AIDS       Date:  2018-01-14       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.